179 related articles for article (PubMed ID: 33667957)
1. Gold nanoparticles conjugated with programmed death-ligand 1 antibodies induce apoptosis of SCC-25 oral squamous cell carcinoma cells via programmed death-ligand 1/signal transducer and transcription 3 pathway.
Choi BBR; Choi JH; Kim UK; Hwang DS; Kim GC
Arch Oral Biol; 2021 May; 125():105085. PubMed ID: 33667957
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling.
Cui B; Chen J; Luo M; Wang L; Chen H; Kang Y; Wang J; Zhou X; Feng Y; Zhang P
Int J Oncol; 2020 Apr; 56(4):909-920. PubMed ID: 32319563
[TBL] [Abstract][Full Text] [Related]
3. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
PeerJ; 2023; 11():e15922. PubMed ID: 37663280
[TBL] [Abstract][Full Text] [Related]
4. JAK2 regulation by licochalcone H inhibits the cell growth and induces apoptosis in oral squamous cell carcinoma.
Oh HN; Oh KB; Lee MH; Seo JH; Kim E; Yoon G; Cho SS; Cho YS; Choi HW; Chae JI; Shim JH
Phytomedicine; 2019 Jan; 52():60-69. PubMed ID: 30599913
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells.
Lee JH; Lee DY; Lee HJ; Im E; Sim DY; Park JE; Park WY; Shim BS; Kim SH
Cells; 2021 Aug; 10(8):. PubMed ID: 34440920
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-L1-modified and ATRA-loaded nanoparticles for immuno-treatment of oral dysplasia and oral squamous cell carcinoma.
Chen XJ; Zhang XQ; Tang MX; Liu Q; Zhou G
Nanomedicine (Lond); 2020 Apr; 15(10):951-968. PubMed ID: 32255397
[No Abstract] [Full Text] [Related]
7. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1).
Michikawa C; Gopalakrishnan V; Harrandah AM; Karpinets TV; Garg RR; Chu RA; Park YP; Chukkapallia SS; Yadlapalli N; Erikson-Carter KC; Gleber-Netto FO; Sayour E; Progulske-Fox A; Chan EKL; Wu X; Zhang J; Jobin C; Wargo JA; Pickering CR; Myers JN; Silver N
Neoplasia; 2022 Sep; 31():100813. PubMed ID: 35834946
[TBL] [Abstract][Full Text] [Related]
8. Contribution of p38 MAPK Pathway to Norcantharidin-Induced Programmed Cell Death in Human Oral Squamous Cell Carcinoma.
Ahn CH; Hong KO; Jin B; Lee W; Jung YC; Lee H; Shin JA; Cho SD; Hong SD
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31315217
[TBL] [Abstract][Full Text] [Related]
9. CircKRT1 drives tumor progression and immune evasion in oral squamous cell carcinoma by sponging miR-495-3p to regulate PDL1 expression.
Yang Z; Chen W; Wang Y; Qin M; Ji Y
Cell Biol Int; 2021 Jul; 45(7):1423-1435. PubMed ID: 33675276
[TBL] [Abstract][Full Text] [Related]
10. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
[TBL] [Abstract][Full Text] [Related]
11. All-trans retinoic acid induces anti-tumor effects via STAT3 signaling inhibition in oral squamous cell carcinoma and oral dysplasia.
Chen XJ; He MJ; Zhou G
J Oral Pathol Med; 2019 Oct; 48(9):832-839. PubMed ID: 31323146
[TBL] [Abstract][Full Text] [Related]
12. Silencing Signal Transducer and Activator of Transcription 3 (STAT3) and Use of Anti-Programmed Cell Death-Ligand 1 (PD-L1) Antibody Induces Immune Response and Anti-Tumor Activity.
Wang J; Huang F; Jiang C; Chi P
Med Sci Monit; 2020 Apr; 26():e915854. PubMed ID: 32343679
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
Ren J
Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
[TBL] [Abstract][Full Text] [Related]
14. Induction of Melanoma Cell-Selective Apoptosis Using Anti-HER2 Antibody-Conjugated Gold Nanoparticles.
Jeon HJ; Choi BBR; Park KH; Hwang DS; Kim UK; Kim GC
Yonsei Med J; 2019 Jun; 60(6):509-516. PubMed ID: 31124333
[TBL] [Abstract][Full Text] [Related]
15. The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.
Nieto C; Miller B; Alzofon N; Chimed T; Himes J; Joshi M; Gomez K; Chowdhury FN; Le PN; Weaver A; Somerset H; Morton JJ; Wang JH; Wang XJ; Gao D; Hansen K; Keysar SB; Jimeno A
J Natl Cancer Inst; 2023 Nov; 115(11):1392-1403. PubMed ID: 37389416
[TBL] [Abstract][Full Text] [Related]
16. A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy.
Liu D; Wang J; You W; Ma F; Sun Q; She J; He W; Yang G
Front Immunol; 2023; 14():1228581. PubMed ID: 37529049
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic activity of genipin in human oral squamous cell carcinoma in vitro by regulating STAT3 signaling.
Park DG; Jin B; Lee WW; Kim HJ; Kim JH; Choi SJ; Hong SD; Shin JA; Cho SD
Cell Biochem Funct; 2023 Dec; 41(8):1319-1329. PubMed ID: 37792550
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
Bhowmik T; Gomes A
Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
20. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
